Commonly reported side effects include somnolence, dizziness, fatigue, and ataxia. No laboratory abnormalities have been reported. Because it is not metabolized by the liver and because it is not protein bound, it does not interact with other AEDs. Its absorption can be slowed by antacids, and therefore, it is recommended that GBP not be taken with these medications. It has been proved effective as adjunctive treatment of refractory partial seizures and generalized tonic-clonic seizures.
Larger dosages appear to be more effective than smaller ones.
In addition, it may be effective for benign rolandic epilepsy of childhood. Since the drug is not metabolized by the liver, it may be an effective AED for patients with porphyria. It is not effective against absence seizures in children. There appears to be no correlation between serum concentration and clinical efficacy. LTG is produced by the Burroughs-Wellcome company and is released as Lamictal .